What Is Biphasic Mesothelioma?
Biphasic mesothelioma contains both epithelioid and sarcomatoid cells. It accounts for 20% to 30% of cases, and its prognosis depends on the ratio of the two cell types — a higher proportion of epithelioid cells generally means better treatment response and longer survival.
Understanding Biphasic Mesothelioma
Biphasic mesothelioma is defined by the presence of both epithelioid and sarcomatoid cell types within the same tumor. To be classified as biphasic, a tumor must contain at least 10% of each cell type. This mixed composition means that each biphasic case is unique, and prognosis depends heavily on the specific proportion of cells present.
Accurate diagnosis of biphasic mesothelioma requires an adequate tissue sample, typically obtained through a surgical biopsy rather than a fine-needle aspiration. Smaller samples may only capture one cell type, leading to an incomplete or incorrect classification that could affect treatment decisions.
How Cell Ratio Affects Prognosis
The relative proportion of epithelioid and sarcomatoid cells is the primary determinant of biphasic mesothelioma prognosis. Tumors with a predominantly epithelioid component (more than 50% epithelioid cells) tend to behave more like pure epithelioid mesothelioma, with better treatment response and longer survival.
Conversely, biphasic tumors with a high percentage of sarcomatoid cells tend to be more aggressive and resistant to treatment. Research has shown that the percentage of sarcomatoid cells is an independent predictor of survival, with each increase in sarcomatoid proportion associated with incrementally poorer outcomes.
Treatment Approach
Treatment for biphasic mesothelioma typically follows the same general framework as other mesothelioma types, with the approach tailored to the cell ratio and stage. Patients with predominantly epithelioid biphasic tumors may be candidates for surgical resection combined with chemotherapy. Those with higher sarcomatoid components may benefit more from immunotherapy-based regimens.
Consulting with experienced mesothelioma specialists is essential for biphasic patients. Understanding your legal options for compensation can help cover the costs of specialized treatment and provide financial stability for your family during a difficult time.
- Frequency: 20–30% of all mesothelioma diagnoses
- Median Survival: 8–14 months, depending on cell ratio
- Key Factor: Prognosis improves as the proportion of epithelioid cells increases
- Diagnosis: Requires adequate tissue sample to accurately assess cell ratio
Reviewed by: Rod De Llano, J.D. — Texas Bar — 30+ years mesothelioma litigation
Last updated: March 15, 2026
Sources: Archives of Pathology & Laboratory Medicine — Biphasic Malignant Mesothelioma, Lung Cancer — Prognostic Significance of Biphasic Histology in Mesothelioma, American Journal of Surgical Pathology — Mesothelioma Histological Classification
Our attorneys have handled mesothelioma cases for over 30 years. We can evaluate your situation, explain every option available to you, and answer your questions — all at no cost and with no obligation.
Request a Free Consultation
Your information is confidential and protected. We typically respond within 24 hours.
Call 1-800-400-1805 for immediate help.